Homoharringtonine plus hormone therapy before prostate surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a drug called homoharringtonine (a type of chemotherapy) to standard hormone therapy before prostate surgery can improve outcomes for men with certain stages of prostate cancer. It's for men who haven't had any previous treatment and plan to have their prostate removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You must have prostate cancer confirmed by biopsy or other test.
- Your cancer must be either high-risk or very high-risk localized, spread only to nearby lymph nodes, or spread to other parts of the body.
- You must be able to carry out daily activities without help (ECOG score 0 or 1).
- You cannot have had any prior treatment for prostate cancer (including hormone therapy, chemo, or radiation).
- You must plan to have surgery to remove your prostate (radical prostatectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
This trial tests a combination of drugs given before prostate removal surgery. The goal is to see if this treatment can shrink or slow high-risk prostate cancer.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.